OVID Ovid Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OVID

Price (delayed)

$3.1

Market cap

$219.2M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.74

Enterprise value

$236.23M

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. The company believes these ...

Highlights
OVID's revenue has dropped by 74% year-on-year but it is up by 32% since the previous quarter
The gross profit has plunged by 74% YoY but it has grown by 32% from the previous quarter
Ovid Therapeutics's debt has surged by 182% QoQ and by 178% YoY
OVID's quick ratio is down by 50% YoY and by 9% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ovidrx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of OVID
Market
Shares outstanding
70.71M
Market cap
$219.2M
Enterprise value
$236.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.5
Price to sales (P/S)
558.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
603.1
Earnings
Revenue
$391,695
EBIT
-$52.34M
EBITDA
-$50.74M
Free cash flow
-$45.82M
Per share
EPS
-$0.74
Free cash flow per share
-$0.65
Book value per share
$1.24
Revenue per share
$0.01
TBVPS
$2.04
Balance sheet
Total assets
$144.03M
Total liabilities
$56.23M
Debt
$46M
Equity
$87.8M
Working capital
$98.12M
Liquidity
Debt to equity
0.52
Current ratio
9.55
Quick ratio
9.39
Net debt/EBITDA
-0.34
Margins
EBITDA margin
-12,954.6%
Gross margin
100%
Net margin
-13,362.2%
Operating margin
-15,134.6%
Efficiency
Return on assets
-38.2%
Return on equity
-49.8%
Return on invested capital
-55.1%
Return on capital employed
-39.5%
Return on sales
-13,362.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OVID stock price

How has the Ovid Therapeutics stock price performed over time
Intraday
3.68%
1 week
-4.02%
1 month
3.33%
1 year
-6.63%
YTD
-3.73%
QTD
1.64%

Financial performance

How have Ovid Therapeutics's revenue and profit performed over time
Revenue
$391,695
Gross profit
$391,695
Operating income
-$59.28M
Net income
-$52.34M
Gross margin
100%
Net margin
-13,362.2%
OVID's revenue has dropped by 74% year-on-year but it is up by 32% since the previous quarter
The gross profit has plunged by 74% YoY but it has grown by 32% from the previous quarter
Ovid Therapeutics's net margin has increased by 18% QoQ
The operating margin has grown by 16% from the previous quarter

Growth

What is Ovid Therapeutics's growth rate over time

Valuation

What is Ovid Therapeutics stock price valuation
P/E
N/A
P/B
2.5
P/S
558.6
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
603.1
The EPS is down by 7% QoQ but it is up by 3.9% YoY
OVID's equity is down by 34% YoY and by 13% from the previous quarter
OVID's price to book (P/B) is 14% more than its last 4 quarters average of 2.2 but 7% less than its 5-year quarterly average of 2.7
OVID's revenue has dropped by 74% year-on-year but it is up by 32% since the previous quarter
OVID's price to sales (P/S) is 46% less than its last 4 quarters average of 1033.1

Efficiency

How efficient is Ovid Therapeutics business performance
Ovid Therapeutics's ROE has decreased by 36% YoY and by 19% from the previous quarter
The return on assets has declined by 21% year-on-year and by 10% since the previous quarter
The ROS is up by 18% QoQ

Dividends

What is OVID's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OVID.

Financial health

How did Ovid Therapeutics financials performed over time
Ovid Therapeutics's total assets is 156% more than its total liabilities
The total liabilities has soared by 145% YoY and by 137% from the previous quarter
OVID's quick ratio is down by 50% YoY and by 9% QoQ
Ovid Therapeutics's debt is 48% lower than its equity
Ovid Therapeutics's debt has surged by 182% QoQ and by 178% YoY
OVID's equity is down by 34% YoY and by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.